

Medicare Advantage Provider Bulletin



News and Information

May 15, 2025

Ketamine Infusion Policy

On July 1, 2025, Aspirus Health Plan's Ketamine intravenous drug policy takes effect for Aspirus Health Plan Medicare Advantage members. Ketamine is considered investigational for the following conditions and will not be covered:

- Psychiatric disorders (including, but not limited to depression, bipolar disorder and posttraumatic stress disorder)
- Chronic pain (including, but not limited to nonmalignant pain, fibromyalgia, neuropathic pain, Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy)
- Headaches

Prior authorization is not applicable for Ketamine infusions as it is considered excluded for these investigational uses. Additionally, Aspirus Health Plan will not review excluded uses for medical necessity.

Policy

Providers will find this policy in [Aspirus Health Plan's Medical Drug Policies](#) library on July 1, 2025.

Contact Aspirus Health Plan's Provider Assistance Center at 715.631.7412 or 1.855.931.4851 toll-free, Monday through Friday, 8 am – 5 pm with questions.

Provider Bulletin

Aspirus Health Plan has partnered with UCare, based out of Minnesota, as the administrator for our Medicare Advantage Plan.

